will rebound also sikit. all this while its profit per quarter also not many.. if you knew.. this time negative so much. need many years to recover.. the share price rebound won't last. when officially in pn17.. will be more red.
PETALING JAYA: Pharmaniaga Bhd has been classified as an affected listed issuer under Practice Note 17 (PN17) of the Main Market Listing Requirements of Bursa Malaysia.
Right issue kot? Cov8d vaccine dah tak laku... Endemic dah
<%-- for fixing scrollbar--%> Save Print Back
7081 PHARMA PHARMANIAGA BHD Quarterly rpt on consolidated results for the financial period ended 31/12/2022 Quarter: 4th Quarter Financial Year End: 31/12/2022 Report Status: Unaudited Submitted By: Current Year Quarter Preceding Year Corresponding Quarter Current Year to Date Preceding Year Corresponding Period 31/12/2022 31/12/2021 31/12/2022 31/12/2021 RM '000 RM '000 RM '000 RM '000 1 Revenue 862,720 711,718 3,510,677 4,815,015 2 Profit/Loss Before Tax (638,395) 125,088 (580,846) 277,075 3 Profit/(loss) attributable to ordinary equity holders of the parent (644,390) 85,475 (607,317) 172,150 4 Net Profit/Loss For The Period (644,197) 85,165 (605,050) 172,205 5 Basic Earnings/Loss Per Shares (sen) (49.19) 6.53 (46.36) 13.15 6 Dividend Per Share (sen) 0.00 5.00 1.90 9.30 As At End of Current Quarter As At Preceding Financial Year End 7 Net Assets Per Share (RM) (0.1900) 0.3440 Remarks: You are advised to read the entire contents of the announcement or attachment. To read the entire contents of the announcement or attachment, please access the Bursa website at http://www.bursamalaysia.com
7081 PHARMA PHARMANIAGA BHD Change in Boardroom Date of Change: 22/02/2023 Type of Change: Cessation Designation: Chief Exec Officer Directorate: Exec Name: ZULKARNAIN MD EUSOPE Age: 55 Country: Nationality: Malaysia Qualifications: Working Experience and Occupation: You are advised to read the entire contents of the announcement or attachment. To read the entire contents of the announcement or attachment, please access the Bursa website at http://www.bursamalaysia.com Directorship of public companies (if any): Family relationship with any director and/or major shareholder of the listed issuer: Nil Details of any interest in the securities of the listed issuer or its subsidiaries: Nil Remarks: Changes are made to align with Boustead Group policy. You are advised to read the entire contents of the announcement or attachment. To read the entire contents of the announcement or attachment, please access the Bursa website at http://www.bursamalaysia.com Submitted By:
Pharma PN17 proven all Malaysia stock can't be simply bought and hold without checking price trend chart regularly and without taking action to cut loss.
I suggest all PN 17 companies to consolidate as one company so that they can hug each other and cry while proposing their regularisation plan in 12 months time.
weird thing is.. even though so much loss.. they still declare dividends. Third Interim Dividend... maybe their directors want dividend for themselves.
It is not easy to make money out of Bursa...during the course of a year, the downs days are more than ups days. So I wud suggest playing short to profit from the market.
I exited this co. @ a pre-bonus $3.993 in Jul '20. After that I believe it even had the nerve to go up to $6! Bonus in Jul '21, PN17 less than 2 years later??? Close shop?
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
nicholas99
9,901 posts
Posted by nicholas99 > 2023-02-28 09:11 | Report Abuse
pn17. gg